Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Xiaobo He, Jianfeng Ding, Xiao Cheng & Maoming Xiong. (2021) Hypoxia-Related Gene-Based Signature Can Evaluate the Tumor Immune Microenvironment and Predict the Prognosis of Colon Adenocarcinoma Patients. International Journal of General Medicine 14, pages 9853-9862.
Read now
Read now
Hamed Manoochehri Khoshinani, Saeid Afshar & Rezvan Najafi. (2016) Hypoxia: A Double-Edged Sword in Cancer Therapy. Cancer Investigation 34:10, pages 536-545.
Read now
Read now
Articles from other publishers (40)
Ryotaro Ohkuma, Yuki Fujimoto, Katsuaki Ieguchi, Nobuyuki Onishi, Makoto Watanabe, Daisuke Takayanagi, Tsubasa Goshima, Atsushi Horiike, Kazuyuki Hamada, Hirotsugu Ariizumi, Yuya Hirasawa, Tomoyuki Ishiguro, Risako Suzuki, Nana Iriguchi, Toshiaki Tsurui, Yosuke Sasaki, Mayumi Homma, Toshiko Yamochi, Kiyoshi Yoshimura, Mayumi Tsuji, Yuji Kiuchi, Shinichi Kobayashi, Takuya Tsunoda & Satoshi Wada. (2023) Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy. Oncology Letters 26:3.
Crossref
Crossref
Ryan C. Perez, DaeHee Kim, Aaron W. P. Maxwell & Juan C. Camacho. (2023) Functional Imaging of Hypoxia: PET and MRI. Cancers 15:13, pages 3336.
Crossref
Crossref
Zhuandi Liu, Xibao Yu, Ling Xu, Yangqiu Li & Chengwu Zeng. (2022) Current insight into the regulation of PD-L1 in cancer. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Qinghua Wu, Li You, Eugenie Nepovimova, Zbynek Heger, Wenda Wu, Kamil Kuca & Vojtech Adam. (2022) Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. Journal of Hematology & Oncology 15:1.
Crossref
Crossref
Yuanling Liu, Minzhen Lu, Jianan Chen, Siqi Li, Yiyu Deng, Shifang Yang, Qiong Ou, Jing Li, Ping Gao, Zeru Luo, Ping Yuan, Jianlong Tan & Xinglin Gao. (2021) Extracellular vesicles derived from lung cancer cells exposed to intermittent hypoxia upregulate programmed death ligand 1 expression in macrophages. Sleep and Breathing 26:2, pages 893-906.
Crossref
Crossref
Shaima Salman, David J. Meyers, Elizabeth E. Wicks, Sophia N. Lee, Emmanuel Datan, Aline M. Thomas, Nicole M. Anders, Yousang Hwang, Yajing Lyu, Yongkang Yang, Walter JacksonIIIIII, Dominic Dordai, Michelle A. Rudek & Gregg L. Semenza. (2022) HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. Journal of Clinical Investigation 132:9.
Crossref
Crossref
Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Takahiro Tomiyama, Akinari Morinaga, Kyohei Yugawa, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Yoshiyuki Kitamura, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Shingo Baba, Kousei Ishigami, Yoshinao Oda & Masaki Mori. (2021) Impact of Nuclear Factor Erythroid 2–Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status. Hepatology Communications 6:4, pages 665-678.
Crossref
Crossref
Wen Li, Feifei Li, Xia Zhang, Hui-Kuan Lin & Chuan Xu. (2021) Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Katrin Pansy, Barbara Uhl, Jelena Krstic, Marta Szmyra, Karoline Fechter, Ana Santiso, Lea Thüminger, Hildegard Greinix, Julia Kargl, Katharina Prochazka, Julia Feichtinger & Alexander JA. Deutsch. (2021) Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. International Journal of Molecular Sciences 22:24, pages 13311.
Crossref
Crossref
Revati Sharma, Elif Kadife, Mark Myers, George Kannourakis, Prashanth Prithviraj & Nuzhat Ahmed. (2021) Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Zhe Deng, Yong-Jie Teng, Qing Zhou, Zhao-Guang Ouyang, Yu-Xing Hu, Hong-Ping Long, Mei-Jie Hu, Si Mei, Feng-Xia Lin, Xin-Jun Dai, Bo-Yu Zhang, Ting Feng & Xue-Fei Tian. (2021) Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 13:11, pages 1725-1740.
Crossref
Crossref
Qiang Wen, Zhe Yang, Honghai Dai, Alei Feng & Qiang Li. (2021) Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features. Frontiers in Oncology 11.
Crossref
Crossref
Lifang Zhang, Yu Zhao, Quanmei Tu, Xiangyang Xue, Xueqiong Zhu & Kong-Nan Zhao. (2021) The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy. Current Medicinal Chemistry 28:5, pages 893-909.
Crossref
Crossref
Nurfarhanah Bte Syed Sulaiman, Chik Hong Kuick, Kenneth T. E. Chang, Kai Rui Wan, Wen Shen Looi, David C. Y. Low, Wan Tew Seow & Sharon Y. Y. Low. (2021) Cytokines in Pediatric Pilocytic Astrocytomas: A Clinico-Pathological Study. NeuroSci 2:1, pages 95-108.
Crossref
Crossref
Yu Fan Zhang, Zhi Hong Zhang, Ming Yue Li, Jing Ying Wang, Yue Xing, MyongHak Ri, Cheng Hua Jin, Guang Hua Xu, Lian Xun Piao, Hong Xiang Zuo, Hong Lan Jin, Juan Ma & Xuejun Jin. (2021) Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1α in cancer. Phytomedicine 81, pages 153425.
Crossref
Crossref
Baotao Chen, Lin Li, Mengyuan Li & Xiaosheng Wang. (2020) HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers. Cellular Oncology 43:5, pages 877-888.
Crossref
Crossref
Huan-Zhen Yang & Xi-Han Zhou. (2020) Mechanism for hypoxia inducible factor-1α to promote immune escape and therapeutic tolerance in hepatocellular carcinoma under hypoxic microenvironment. World Chinese Journal of Digestology 28:18, pages 904-913.
Crossref
Crossref
Christian Sordo-Bahamonde, Massimo Vitale, Seila Lorenzo-Herrero, Alejandro López-Soto & Segundo Gonzalez. (2020) Mechanisms of Resistance to NK Cell Immunotherapy. Cancers 12:4, pages 893.
Crossref
Crossref
Jean-Philippe Brosseau. 2020. Regulation of Cancer Immune Checkpoints. Regulation of Cancer Immune Checkpoints
251
263
.
Soumya R. Mohapatra, Ahmed Sadik, Lars-Oliver Tykocinski, Jørn Dietze, Gernot Poschet, Ines Heiland & Christiane A. Opitz. (2019) Hypoxia Inducible Factor 1α Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma. Frontiers in Immunology 10.
Crossref
Crossref
Yipin Lv, Yongliang Zhao, Xianhua Wang, Na Chen, Fangyuan Mao, Yongsheng Teng, Tingting Wang, Liusheng Peng, Jinyu Zhang, Ping Cheng, Yugang Liu, Hui Kong, Weisan Chen, Chuanjie Hao, Bin Han, Qiang Ma, Quanming Zou, Jun Chen & Yuan Zhuang. (2019) Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Arash Salmaninejad, Saeed Farajzadeh Valilou, Arezoo Gowhari Shabgah, Saeed Aslani, Malihe Alimardani, Alireza Pasdar & Amirhossein Sahebkar. (2019) PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy. Journal of Cellular Physiology 234:10, pages 16824-16837.
Crossref
Crossref
Muhammad Zaeem Noman, Meriem Hasmim, Audrey Lequeux, Malina Xiao, Caroline Duhem, Salem Chouaib, Guy Berchem & Bassam Janji. (2019) Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges. Cells 8:9, pages 1083.
Crossref
Crossref
Yuetao Zhao, Xin-xin Wang, Wei Wu, Haixia Long, Jiani Huang, Zhongyu Wang, Tao Li, Shu Tang, Bo Zhu & Degao Chen. (2019) EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells. Biochemical and Biophysical Research Communications 517:2, pages 201-209.
Crossref
Crossref
Yilun Wu, Weiyu Chen, Zhi Ping Xu & Wenyi Gu. (2019) PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition. Frontiers in Immunology 10.
Crossref
Crossref
Fatemeh K. Dermani, Pouria Samadi, Golebagh Rahmani, Alisa K. Kohlan & Rezvan Najafi. (2018) PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy. Journal of Cellular Physiology 234:2, pages 1313-1325.
Crossref
Crossref
Youcef Rustum, Sreenivasulu Chintala, Farukh Durrani & Arup Bhattacharya. (2018) Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy. International Journal of Molecular Sciences 19:11, pages 3378.
Crossref
Crossref
Barbara Wegiel, Marta Vuerich, Saeed Daneshmandi & Pankaj Seth. (2018) Metabolic Switch in the Tumor Microenvironment Determines Immune Responses to Anti-cancer Therapy. Frontiers in Oncology 8.
Crossref
Crossref
Yiliang Li, Sapna Pradyuman Patel, Jason Roszik & Yong Qin. (2018) Hypoxia-Driven Immunosuppressive Metabolites in the Tumor Microenvironment: New Approaches for Combinational Immunotherapy. Frontiers in Immunology 9.
Crossref
Crossref
Malmaruha Arasaratnam & Howard Gurney. (2018) Nivolumab in the treatment of advanced renal cell carcinoma. Future Oncology 14:17, pages 1679-1689.
Crossref
Crossref
Yiting Wang, Huanbin Wang, Han Yao, Chushu Li, Jing-Yuan Fang & Jie Xu. (2018) Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion. Frontiers in Pharmacology 9.
Crossref
Crossref
Renate Pichler & Isabel Heidegger. (2017) Novel concepts of antiangiogenic therapies in metastatic renal cell cancer. memo - Magazine of European Medical Oncology 10:4, pages 206-212.
Crossref
Crossref
Carolina Cubillos-Zapata, Jose Avendaño-Ortiz, Enrique Hernandez-Jimenez, Victor Toledano, Jose Casas-Martin, Anibal Varela-Serrano, Marta Torres, Isaac Almendros, Raquel Casitas, Isabel Fernández-Navarro, Aldara Garcia-Sanchez, Luis A. Aguirre, Ramón Farre, Eduardo López-Collazo & Francisco García-Rio. (2017) Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea. European Respiratory Journal 50:4, pages 1700833.
Crossref
Crossref
Debashree BasudharVeena SomasundaramGraciele Almeida de OliveiraAparna KesarwalaJulie L. HeineckeRobert Y. ChengSharon A. GlynnStefan AmbsDavid A. WinkLisa A. Ridnour. (2017) Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression. Antioxidants & Redox Signaling 26:18, pages 1044-1058.
Crossref
Crossref
S Chouaib, M Z Noman, K Kosmatopoulos & M A Curran. (2016) Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 36:4, pages 439-445.
Crossref
Crossref
Guido Kroemer & Lorenzo Galluzzi. (2016) Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors. Oncotarget 8:4, pages 5686-5691.
Crossref
Crossref
John N. Waldron & Brian O'Sullivan. (2016) The Challenges of Treatment Adaptation and De-intensification in Human Papillomavirus–Positive Oropharyngeal Cancer: The Difficult Journey Back. International Journal of Radiation Oncology*Biology*Physics 96:1, pages 18-20.
Crossref
Crossref
Muhammad Zaeem Noman, Bassam Janji, Guy Berchem & Salem Chouaib. (2016) miR-210 and hypoxic microvesicles: Two critical components of hypoxia involved in the regulation of killer cells function. Cancer Letters 380:1, pages 257-262.
Crossref
Crossref
Mark W. Dewhirst & Samuel R. Birer. (2016) Oxygen-Enhanced MRI Is a Major Advance in Tumor Hypoxia Imaging. Cancer Research 76:4, pages 769-772.
Crossref
Crossref
Muhammad Zaeem NomanMeriem HasmimYosra MessaiStéphane TerryClaudine Kieda, Bassam Janji & Salem Chouaib. (2015) Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. American Journal of Physiology-Cell Physiology 309:9, pages C569-C579.
Crossref
Crossref